Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of symptoms in respiratory syncytial virus infection in adults: psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire™ symptom scores.
Osborne RH, Nelson LM, Fehnel S, Williams N, Bender RH, Ziemiecki R, Gymnopoulou E, De Paepe E, Vandendijck Y, Norcross L, Heijnen E, Ispas G, Comeaux C, Callendret B, Chan EKH, Scott JA. Osborne RH, et al. Among authors: heijnen e. J Patient Rep Outcomes. 2023 Jun 1;7(1):51. doi: 10.1186/s41687-023-00593-9. J Patient Rep Outcomes. 2023. PMID: 37261682 Free PMC article.
Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries.
Nguyen-Van-Tam JS, O'Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, Comeaux C, Tran TMP, Weber K. Nguyen-Van-Tam JS, et al. Among authors: heijnen e. Eur Respir Rev. 2022 Nov 15;31(166):220105. doi: 10.1183/16000617.0105-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36384703 Free PMC article. Review.
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults.
Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, Menten J, De Paepe E, Vandenberghe S, Chan EKH, Sadoff J, Douoguih M, Callendret B, Comeaux CA, Heijnen E; CYPRESS Investigators. Falsey AR, et al. Among authors: heijnen e. N Engl J Med. 2023 Feb 16;388(7):609-620. doi: 10.1056/NEJMoa2207566. N Engl J Med. 2023. PMID: 36791161 Clinical Trial.
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
Comeaux CA, Bart S, Bastian AR, Klyashtornyy V, De Paepe E, Omoruyi E, van der Fits L, van Heesbeen R, Heijnen E, Callendret B, Sadoff J. Comeaux CA, et al. Among authors: heijnen e. J Infect Dis. 2024 Jan 12;229(1):19-29. doi: 10.1093/infdis/jiad220. J Infect Dis. 2024. PMID: 37433021 Free PMC article. Clinical Trial.
Vaccine-induced antibody Fc-effector functions in humans immunized with a combination Ad26.RSV.preF/RSV preF protein vaccine.
Bartsch YC, Cizmeci D, Yuan D, Mehta N, Tolboom J, De Paepe E, van Heesbeen R, Sadoff J, Comeaux CA, Heijnen E, Callendret B, Alter G, Bastian AR. Bartsch YC, et al. Among authors: heijnen e. J Virol. 2023 Nov 30;97(11):e0077123. doi: 10.1128/jvi.00771-23. Epub 2023 Oct 30. J Virol. 2023. PMID: 37902399 Free PMC article. Clinical Trial.
Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.
Hosman T, van Heesbeen R, Bastian AR, Hu W, Comeaux C, Ligtenberg N, van Montfort B, Callendret B, Heijnen E. Hosman T, et al. Among authors: heijnen e. Hum Vaccin Immunother. 2024 Dec 31;20(1):2344970. doi: 10.1080/21645515.2024.2344970. Epub 2024 May 23. Hum Vaccin Immunother. 2024. PMID: 38783590 Free PMC article. Clinical Trial.
Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.
Falsey AR, Hosman T, Bastian AR, Vandenberghe S, Chan EKH, Douoguih M, Heijnen E, Comeaux CA, Callendret B; CYPRESS investigators. Falsey AR, et al. Among authors: heijnen e. Lancet Infect Dis. 2024 Sep;24(9):1015-1024. doi: 10.1016/S1473-3099(24)00226-3. Epub 2024 May 24. Lancet Infect Dis. 2024. PMID: 38801826 Clinical Trial.
Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material.
Jastorff A, Bastian AR, Ligtenberg N, Klyashtornyy V, Callendret B, Heijnen E. Jastorff A, et al. Among authors: heijnen e. Hum Vaccin Immunother. 2024 Dec 31;20(1):2383504. doi: 10.1080/21645515.2024.2383504. Epub 2024 Aug 8. Hum Vaccin Immunother. 2024. PMID: 39118413 Free PMC article. Clinical Trial.
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.
Langley JM, Nolan TM, Rämet M, Richmond PC, Rosário Filho N, Haazen W, van den Berg SPH, Williams K, Bastian AR, Omoruyi E, Williams Durkin J, Salisch N, Van Geet G, van Duijnhoven W, Heijnen E, Callendret B. Langley JM, et al. Among authors: heijnen e. Open Forum Infect Dis. 2024 Aug 8;11(9):ofae453. doi: 10.1093/ofid/ofae453. eCollection 2024 Sep. Open Forum Infect Dis. 2024. PMID: 39220658 Free PMC article.
47 results